Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

CGP 29287

Known as: CGP-29,287, CGP-29287, L-Lysine, N6-((1,1-dimethylethoxy)carbonyl)-N2-(N-(N-(3-hydroxy-6-methyl-1-oxo-4-((N-(N-(1-(N2-(N2-((phenylmethoxy)carbonyl)-L-arginyl)-L-arginyl)-L-prolyl)-L-phenylalanyl)-L-histidyl)amino)heptyl)-L-isoleucyl)-L-histidyl)-, methyl ester, (S-(R*,R*))- 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1994
1994
To assess the effects of inhibition of the renin-angiotensin system at different levels on plasma concentrations of components of… Expand
1991
1991
A method for the measurement of renal clearances was adapted in a novel manner to the conscious marmoset. Twenty-four hours… Expand
1988
1988
To prevent in vitro generation of angiotensins, the renin inhibitor CGP 29287 (CGP) was added to blood sampling tubes. Plasma… Expand
1987
1987
The primate-specific renin inhibitor CGP 29287 (30 mg/kg/d, n = 5) or the converting-enzyme inhibitor CGS 14831 (30 mg/kg/d, n… Expand